Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Update

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 31,500 shares, a growth of 107.2% from the September 15th total of 15,200 shares. Based on an average daily trading volume, of 45,200 shares, the short-interest ratio is presently 0.7 days. Approximately 2.3% of the company’s stock are short sold.

Institutional Trading of Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Armistice Capital LLC acquired a new stake in Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 75,000 shares of the company’s stock, valued at approximately $262,000. Armistice Capital LLC owned approximately 7.97% of Avenue Therapeutics at the end of the most recent reporting period. 17.34% of the stock is owned by institutional investors.

Avenue Therapeutics Stock Up 2.0 %

Shares of NASDAQ:ATXI opened at $2.06 on Friday. Avenue Therapeutics has a fifty-two week low of $1.90 and a fifty-two week high of $45.75. The firm’s 50 day moving average price is $2.54 and its 200 day moving average price is $4.30. The stock has a market cap of $2.95 million, a price-to-earnings ratio of 0.08 and a beta of -0.17.

Avenue Therapeutics (NASDAQ:ATXI) last announced its quarterly earnings data on Friday, August 9th. The company reported ($6.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($5.38).

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.